300 related articles for article (PubMed ID: 20732513)
1. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.
Kim MP; Correa AM; Lee J; Rice DC; Roth JA; Mehran RJ; Walsh GL; Ajani JA; Maru DM; Chang JY; Marom EM; Macapinlac HA; Lee JH; Vaporciyan AA; Rice T; Swisher SG; Hofstetter WL
Ann Thorac Surg; 2010 Sep; 90(3):884-90; discussion 890-1. PubMed ID: 20732513
[TBL] [Abstract][Full Text] [Related]
2. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
3. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
[TBL] [Abstract][Full Text] [Related]
4. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
5. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.
Rohatgi P; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh GL; Vaporciyan AA; Rice DC; Roth JA; Ajani JA
Cancer; 2005 Dec; 104(11):2365-72. PubMed ID: 16245310
[TBL] [Abstract][Full Text] [Related]
6. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
[TBL] [Abstract][Full Text] [Related]
7. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.
Makary MA; Kiernan PD; Sheridan MJ; Tonnesen G; Hetrick V; Vaughan B; Graling P; Elster E
Am Surg; 2003 Aug; 69(8):693-700; discussion 700-2. PubMed ID: 12953828
[TBL] [Abstract][Full Text] [Related]
8. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
Malaisrie SC; Untch B; Aranha GV; Mohideen N; Hantel A; Pickleman J
Arch Surg; 2004 May; 139(5):532-8; discussion 538-9. PubMed ID: 15136354
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of pathologic examination in detection of complete response after chemoradiation for esophageal cancer.
Chang EY; Smith CA; Corless CL; Thomas CR; Hunter JG; Jobe BA
Am J Surg; 2007 May; 193(5):614-7; discussion 617. PubMed ID: 17434367
[TBL] [Abstract][Full Text] [Related]
12. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
[TBL] [Abstract][Full Text] [Related]
13. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
14. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus.
Forastiere AA; Heitmiller RF; Lee DJ; Zahurak M; Abrams R; Kleinberg L; Watkins S; Yeo CJ; Lillemoe KD; Sitzmann JV; Sharfman W
Cancer J Sci Am; 1997; 3(3):144-52. PubMed ID: 9161779
[TBL] [Abstract][Full Text] [Related]
16. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
17. Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens.
Thompson SK; Ruszkiewicz AR; Jamieson GG; Esterman A; Watson DI; Wijnhoven BP; Lamb PJ; Devitt PG
Ann Surg Oncol; 2008 Dec; 15(12):3447-58. PubMed ID: 18830669
[TBL] [Abstract][Full Text] [Related]
18. How does the number of resected lymph nodes influence TNM staging and prognosis for esophageal carcinoma?
Hu Y; Hu C; Zhang H; Ping Y; Chen LQ
Ann Surg Oncol; 2010 Mar; 17(3):784-90. PubMed ID: 19953333
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas.
Kato H; Fukuchi M; Manda R; Faried A; Takita J; Nakajima M; Miyazaki T; Sohda M; Fukai Y; Masuda N; Tsukada K; Kuwano H
Anticancer Res; 2004; 24(6):4091-6. PubMed ID: 15736457
[TBL] [Abstract][Full Text] [Related]
20. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
